H.C. Nickel et al. / European Journal of Medicinal Chemistry 45 (2010) 3420e3438
3437
[26] H.S. Huang, H.F. Chiu, J.M. Hwang, Y.M. Jen, C.W. Tao, K.Y. Lee, Y.L. Lai, Studies
on anthracenes. 2. Synthesis and cytotoxic evaluation of 9-acyloxy 1,8-
dichloroanthracene derivatives. Chem. Pharm. Bull. (Tokyo) 49 (2001)
1346e1348.
[27] K. Müller, D. Gürster, S. Piwek, W. Wiegrebe, Antipsoriatic anthrones with
modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-
anthracenones as inhibitors of 5-lipoxygenase. J. Med. Chem. 36 (1993)
4099e4107.
[28] H. Auterhoff, F.C. Scherff, Die dianthrone der pharmazeutisch interessier-
enden Hydroxyanthrachinone. Arch. Pharm. 293 (1960) 918e925.
[29] H. Prinz, W. Wiegrebe, K. Müller, Syntheses of anthracenones. 1. Sodium
dithionite reduction of peri-substituted anthracenediones. J. Org. Chem. 61
(1996) 2853e2856.
References
[1] S. Honore, E. Pasquier, D. Braguer, Understanding microtubule dynamics for
improved cancer therapy. Cell. Mol. Life Sci. 62 (2005) 3039e3056.
[2] F. Pellegrini, D.R. Budman, Review: tubulin function, action of antitubulin
drugs, and new drug development. Cancer Invest. 23 (2005) 264e273.
[3] B.R. Hearn, S.J. Shaw, D.C. Myles, Microtubule targeting agents. Comp. Med.
Chem. 7 (2007) 81e110.
[4] M.A. Jordan, Mechanism of action of antitumor drugs that interact with
microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2 (2002) 1e17.
[5] Q. Li, H.L. Sham, Discovery and development of antimitotic agents that inhibit
tubulin polymerisation for the treatment of cancer. Expert Opin. Ther. Pat. 12
(2002) 1663e1702.
[6] N. Mahindroo, J.P. Liou, J.Y. Chang, H.P. Hsieh, Antitubulin agents for the
treatment of cancer e a medicinal chemistry update. Expert Opin. Ther. Pat.
16 (2006) 647e691.
[7] G.R. Pettit, S.B. Singh, E. Hamel, C.M. Lin, D.S. Alberts, D. Garcia-Kendall,
Isolation and structure of the strong cell growth and tubulin inhibitor com-
bretastatin A-4. Experientia 45 (1989) 209e211.
[8] S. Goodin, M.P. Kane, E.H. Rubin, Epothilones: mechanism of action and bio-
logic activity. J. Clin. Oncol. 22 (2004) 2015e2025.
[9] K. Yoshimatsu, A. Yamaguchi, H. Yoshino, N. Koyanagi, K. Kitoh, Mechanism of
action of E7010, an orally active sulfonamide antitumor agent: inhibition of
mitosis by binding to the colchicine site of tubulin. Cancer Res. 57 (1997)
3208e3213.
[10] S. Arora, X.I. Wang, S.M. Keenan, C. Andaya, Q. Zhang, Y. Peng, W.J. Welsh,
Novel microtubule polymerization inhibitor with potent antiproliferative and
antitumor activity. Cancer Res. 69 (2009) 1910e1915.
[11] S. Baasner, P. Emig, M. Gerlach, G. Müller, K. Paulini, P. Schmidt, A.M. Burger,
H.-H. Fiebig, E.G. Günther, D-82318-A novel, synthetic, low molecular weight
tubulin inhibitor with potent in vivo antitumor activity, poster 112; EORTC-
NCI-AACR meeting Frankfurt, (2002).
[12] F. Meng, X. Cai, J. Duan, M.G. Matteucci, C.P. Hart, A novel class of tubulin
inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting
activity. Cancer Chemother. Pharmacol. 61 (2008) 953e963.
[13] L.H. Zhang, L. Wu, H.K. Raymon, R.S. Chen, L. Corral, M.A. Shirley, R.K. Narla,
J. Gamez, G.W. Muller, D.I. Stirling, J.B. Bartlett, P.H. Schafer, F. Payvandi, The
synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization
and tumor necrosis factor-alpha production with antitumor activity. Cancer
Res. 66 (2006) 951e959.
[14] J.A. Hadfield, S. Ducki, N. Hirst, A.T. McGown, Tubulin and microtubules as
targets for anticancer drugs. Prog. Cell Cycle Res. 5 (2003) 309e325.
[15] D.G. Kingston, Tubulin-interactive natural products as anticancer agents (1). J.
Nat. Prod. 72 (2009) 507e515.
[16] H. Prinz, Y. Ishii, T. Hirano, T. Stoiber, J.A. Camacho Gomez, P. Schmidt,
H. Düssmann, A.M. Burger, J.H. Prehn, E.G. Günther, E. Unger, K. Umezawa,
Novel benzylidene-9(10 H)-anthracenones as highly active antimicrotubule
agents. Synthesis, antiproliferative activity, and inhibition of tubulin poly-
merization. J. Med. Chem. 46 (2003) 3382e3394.
[17] A. Zuse, P. Schmidt, S. Baasner, K.J. Böhm, K. Müller, M. Gerlach, E.G. Günther,
E. Unger, H. Prinz, 9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel
antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of
tubulin polymerization. J. Med. Chem. 49 (2006) 7816e7825.
[18] A. Zuse, P. Schmidt, S. Baasner, K.J. Böhm, K. Müller, M. Gerlach, E.G. Günther,
E. Unger, H. Prinz, Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9 H)-
one and 9(10 H)-anthracenone as highly active antimicrotubule agents.
Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
J. Med. Chem. 50 (2007) 6059e6066.
[19] H. Prinz, P. Schmidt, K.J. Böhm, S. Baasner, K. Müller, E. Unger, M. Gerlach, E.
G. Günther, 10-(2-oxo-2-Phenylethylidene)-10 H-anthracen-9-ones as highly
active antimicrotubule agents: synthesis, antiproliferative activity, and inhi-
bition of tubulin polymerization. J. Med. Chem. 52 (2009) 1284e1294.
[20] H.S. Huang, J.F. Chiou, H.F. Chiu, R.F. Chen, Y.L. Lai, Synthesis and cytotoxicity
of 9-alkoxy-1,5-dichloroanthracene derivatives in murine and human
cultured tumor cells. Arch. Pharm. (Weinheim) 335 (2002) 33e38.
[21] H.S. Huang, J.F. Chiou, H.F. Chiu, J.M. Hwang, P.Y. Lin, C.W. Tao, P.F. Yeh, W.
R. Jeng, Synthesis of symmetrical 1,5-bis-thio-substituted anthraquinones for
cytotoxicity in cultured tumor cells and lipid peroxidation. Chem. Pharm. Bull.
(Tokyo) 50 (2002) 1491e1494.
[30] S.M.M. El-Shafie, Synthesis of 10-arylidene-9-anthrones
compounds. Indian J. Chem. 16B (1978) 828e830.
&
related
[31] H.O. House, N.I. Ghali, J.L. Haack, D. VanDerveer, Reactions of the 1,8-diphe-
nylanthracene system. J. Org. Chem. 45 (1980) 1807e1817.
[32] H.-S. Huang, J.-M. Hwang, Y.-M. Jen, C.-W. Tao, K.-Y. Lee, C.-H. Shi, Chromo-
phore-modified antitumor anthracenes. 1. Cytotoxic activity of 9-acyloxy-1,5-
dichloroanthracene analogs. Chinese Pharm. J. 53 (2001) 71e83.
[33] C.B. Lozzio, B.B. Lozzio, Human chronic myelogenous leukemia cell-line with
positive philadelphia chromosome. Blood 45 (1975) 321e334.
[34] K. Müller, D. Gürster, Hydroxyl radical damage to DNA sugar and model
membranes induced by anthralin (dithranol). Biochem. Pharmacol. 46 (1993)
1695e1704.
[35] D.A. Scudiero, R.H. Shoemaker, K.D. Paull, A. Monks, S. Tierney, T.H. Nofziger,
M.J. Currens, D. Seniff, M.R. Boyd, Evaluation of a soluble tetrazolium/for-
mazane assay for cell growth and drug sensitivity in culture using human and
other tumor cell lines. Cancer Res. 48 (1988) 4827e4833.
[36] M. Schmidt, Y. Lu, J.M. Parant, G. Lozano, G. Bacher, T. Beckers, Z. Fan,
Differential roles of p21Waf1 and p27Kip1 in modulating chemosensitivity and
their possible application in drug discovery studies. Mol. Pharmacol. 60 (2001)
900e906.
[37] C. Dumontet, J.P. Jaffrezou, E. Tsuchiya, G.E. Duran, G. Chen, W.B. Derry,
L. Wilson, M.A. Jordan, B.I. Sikic, Resistance to microtubule-targeted cyto-
toxins in
a K562 leukemia cell variant associated with altered tubulin
expression and polymerization. Bull. Cancer 91 (2004) 81e112.
[38] M. Kavallaris, J.P. Annereau, J.M. Barret, Potential mechanisms of resistance to
microtubule inhibitors. Semin. Oncol. 35 (2008) 22e27.
[39] N.M. Verrills, M. Kavallaris, Improving the targeting of tubulin-binding agents:
lessons from drug resistance studies. Curr. Pharm. Design 11 (2005)
1719e1733.
[40] C. Kanthou, O. Greco, A. Stratford, I. Cook, R. Knight, O. Benzakour, G. Tozer,
The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial
cells in mitosis and induces mitotic cell death. Am. J. Pathol. 165 (2004)
1401e1411.
[41] D. Simoni, G. Grisolia, G. Giannini, M. Roberti, R. Rondanin, L. Piccagli,
R. Baruchello, M. Rossi, R. Romagnoli, F.P. Invidiata, S. Grimaudo, M.K. Jung,
E. Hamel, N. Gebbia, L. Crosta, V. Abbadessa, A. Di Cristina, L. Dusonchet,
M. Meli, M. Tolomeo, Heterocyclic and phenyl double-bond-locked com-
bretastatin analogues possessing potent apoptosis-inducing activity in HL60
and in MDR cell lines. J. Med. Chem. 48 (2005) 723e736.
[42] S. Ducki, R. Forrest, J.A. Hadfield, A. Kendall, N.J. Lawrence, A.T. McGown,
D. Rennison, Potent antimitotic and cell growth inhibitory properties of
substituted chalcones. Bioorg. Med. Chem. Lett. 8 (1998) 1051e1056.
[43] G.R. Pettit, M.R. Rhodes, D.L. Herald, E. Hamel, J.M. Schmidt, R.K. Pettit,
Antineoplastic agents. 445. Synthesis and evaluation of structural modifi-
cations of (Z)- and (E)-combretastatin A-41. J. Med. Chem. 48 (2005)
4087e4099.
[44] Y. Schneider, P. Chabert, J. Stutzmann, D. Coelho, A. Fougerousse, F. Gosse, J.
F. Launay, R. Brouillard, F. Raul, Resveratrol analog (Z)-3,5,4’-trimethox-
ystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int. J.
Cancer 107 (2003) 189e196.
[45] F. Mu, E. Hamel, D.J. Lee, D.E. Pryor, M. Cushman, Synthesis, anticancer
activity, and inhibition of tubulin polymerization by conformationally
restricted analogues of lavendustin A. J. Med. Chem. 46 (2003)
1670e1682.
[46] M. Cushman, H.-M. He, J.A. Katzenellenbogen, R.K. Varma, E. Hamel, C.M. Lin,
S. Ram, Y.P. Sachdeva, Synthesis of analogs of 2-methoxyestradiol with
enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
J. Med. Chem. 40 (1997) 2323e2334.
[22] H.S. Huang, H.F. Chiu, W.C. Lu, C.L. Yuan, Synthesis and antitumor activity of
1,8-diaminoanthraquinone derivatives. Chem. Pharm. Bull. (Tokyo) 53 (2005)
1136e1139.
[23] E.M. Perchellet, Y. Wang, K. Lou, H. Zhao, S.K. Battina, D.H. Hua, J.P. Perchellet,
Novel substituted 1,4-anthracenediones with antitumor activity directly
induce permeability transition in isolated mitochondria. Int. J. Oncol. 31
(2007) 1231e1241.
[24] G. Zagotto, C. Sissi, L. Lucatello, C. Pivetta, S.A. Cadamuro, K.R. Fox, S. Neidle,
M. Palumbo, Aminoacyl-anthraquinone conjugates as telomerase inhibitors:
synthesis, biophysical and biological evaluation. J. Med. Chem. 51 (2008)
5566e5574.
[25] H.S. Huang, H.F. Chiu, J.F. Chiou, P.F. Yeh, C.W. Tao, W.R. Jeng, Synthesis of
symmetrical 1,5-bisacyloxyanthraquinone derivatives and their dual activity
of cytotoxicity and lipid peroxidation. Arch. Pharm. (Weinheim) 335 (2002)
481e486.
[47] M. Cushman, D. Nagarathnam, D. Gopal, A.K. Chakraborti, C.M. Lin, E. Hamel,
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as
potential anticancer agents that inhibit tubulin polymerization. J. Med. Chem.
34 (1991) 2579e2588.
[48] B. Oertel, W. Vater, E.-M. Wiederhold, W. Schulze, J. Baumgart, K.J. Böhm,
E. Jelke, I.S. Tint, V. Viklicky, E. Unger, Fluorenone-azomethines, a novel class
of microtubule inhibitors that specifically affect cell proliferation. Acta His-
tochem. 92 (1992) 74e86.
[49] S.K. Tahir, P. Kovar, S. Rosenberg, S.-C. Ng, A rapid colchicine competition-
binding scintillation proximity assay using biotin-labeled colchicine. Bio-
techniques 29 (2000) 156e160.
[50] R. Bai, M.C. Roach, S.K. Jayaram, J. Barkoczy, G.R. Pettit, R.F. Luduena, E. Hamel,
Differential effects of active isomers, segments, and analogs of dolastatin 10